Zepbound (tirzepatide) has not yet received FDA approval for use in 2025. The drug is currently under FDA review for its weight loss indication.
When is Zepbound expected to be approved for weight loss?
The FDA has not set a specific approval date for Zepbound's weight loss indication in 2025. The review process is ongoing.
What is tirzepatide approved for currently?
Tirzepatide is currently approved by the FDA under the brand name Mounjaro for the treatment of type 2 diabetes [1].
What is Zepbound's mechanism of action?
Zepbound and Mounjaro contain tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. This dual action is believed to contribute to its effects on blood sugar control and appetite [1].
What is the difference between Zepbound and Mounjaro?
Zepbound is the brand name for tirzepatide when indicated for chronic weight management. Mounjaro is the brand name for tirzepatide when indicated for type 2 diabetes [1]. While the active ingredient is the same, the FDA approval and labeling differ based on the intended medical condition.
What clinical trials support Zepbound's weight loss indication?
The FDA's review of tirzepatide for weight loss is based on studies such as the SURMOUNT-1 trial. This trial demonstrated significant weight loss in adults with overweight or obesity, without diabetes, treated with tirzepatide [1].
What are the potential side effects of tirzepatide?
Common side effects reported for tirzepatide (Mounjaro) include nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain [1]. More serious risks can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid C-cell tumors [1].
What is the outlook for tirzepatide in the obesity market?
The potential for tirzepatide in the obesity market is significant, with analysts and market watchers anticipating it to be a major competitor in the weight management space [2]. However, availability and market penetration will depend on final FDA approval and manufacturing capacity.
Who manufactures tirzepatide (Zepbound/Mounjaro)?
Tirzepatide is manufactured by Eli Lilly and Company [1].
Are there patents for tirzepatide?
Eli Lilly holds patents related to tirzepatide. Information regarding patent expiry and any associated patent challenges can be found on specialized drug patent tracking websites [3].
Sources:
1. DrugPatentWatch.com
2. Reuters. (2023, November 8). Eli Lilly's Zepbound approved by FDA for weight loss. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-eli-lillys-tirzepatide-drug-weight-loss-2023-11-08/
3. DrugPatentWatch.com